# Varex Imaging Corp: financial statements, quarterly VREX · Nasdaq · CIK 1681622 · [Technology](/sectors/technology.md) · fiscal year ends Oct 2 Pages: [Overview](/companies/vrex.md) · [Financials](/companies/vrex/financials.md) · [Filings](/companies/vrex/filings.md) · [Insiders](/companies/vrex/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vrex/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-09-29) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | Q4 FY2024 (2024-09-27) | Q1 FY2025 (2025-01-03) | Q2 FY2025 (2025-04-04) | Q3 FY2025 (2025-07-04) | Q4 FY2025 (2025-10-03) | Q1 FY2026 (2026-01-02) | Q2 FY2026 (2026-04-03) | Q3 FY2026 (2026-07-03) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [227 d](/filings/0001681622-25-000108.md) | [190](/filings/0001681622-25-000015.md) | [206](/filings/0001681622-25-000063.md) | [209](/filings/0001681622-25-000084.md) | [206 d](/filings/0001681622-25-000108.md) | [200](/filings/0001681622-26-000016.md) | [213](/filings/0001681622-26-000052.md) | [203](/filings/0001681622-26-000063.md) | [229 d](/filings/0001681622-25-000108.md) | [210](/filings/0001681622-26-000016.md) | [216](/filings/0001681622-26-000052.md) | [211](/filings/0001681622-26-000063.md) | | Cost of revenue | $m | [149 d](/filings/0001681622-25-000108.md) | [133](/filings/0001681622-25-000015.md) | [140](/filings/0001681622-25-000063.md) | [142](/filings/0001681622-25-000084.md) | [139 d](/filings/0001681622-25-000108.md) | [131](/filings/0001681622-26-000016.md) | [136](/filings/0001681622-26-000052.md) | [136](/filings/0001681622-26-000063.md) | [151 d](/filings/0001681622-25-000108.md) | [140](/filings/0001681622-26-000016.md) | [143](/filings/0001681622-26-000052.md) | [134](/filings/0001681622-26-000063.md) | | Gross profit | $m | [78.0 d](/filings/0001681622-25-000108.md) | [57.1](/filings/0001681622-25-000015.md) | [65.8](/filings/0001681622-25-000063.md) | [66.9](/filings/0001681622-25-000084.md) | [67.1 d](/filings/0001681622-25-000108.md) | [68.5](/filings/0001681622-26-000016.md) | [76.7](/filings/0001681622-26-000052.md) | [67.5](/filings/0001681622-26-000063.md) | [77.8 d](/filings/0001681622-25-000108.md) | [69.8](/filings/0001681622-26-000016.md) | [72.6](/filings/0001681622-26-000052.md) | [76.7](/filings/0001681622-26-000063.md) | | Research and development | $m | [21.8 d](/filings/0001681622-25-000108.md) | [20.5](/filings/0001681622-25-000015.md) | [22.6](/filings/0001681622-25-000063.md) | [22.0](/filings/0001681622-25-000084.md) | [21.9 d](/filings/0001681622-25-000108.md) | [23.5](/filings/0001681622-26-000016.md) | [22.0](/filings/0001681622-26-000052.md) | [21.4](/filings/0001681622-26-000063.md) | [24.2 d](/filings/0001681622-25-000108.md) | [21.7](/filings/0001681622-26-000016.md) | [22.2](/filings/0001681622-26-000052.md) | [23.3](/filings/0001681622-26-000063.md) | | Selling, general and administrative | $m | [31.9 d](/filings/0001681622-25-000108.md) | [32.4](/filings/0001681622-25-000015.md) | [35.5](/filings/0001681622-25-000063.md) | [35.6](/filings/0001681622-25-000084.md) | [34.3 d](/filings/0001681622-25-000108.md) | [33.8](/filings/0001681622-26-000016.md) | [32.6](/filings/0001681622-26-000052.md) | [32.9](/filings/0001681622-26-000063.md) | [34.0 d](/filings/0001681622-25-000108.md) | [32.7](/filings/0001681622-26-000016.md) | [36.0](/filings/0001681622-26-000052.md) | [30.6](/filings/0001681622-26-000063.md) | | Operating income | $m | [24.3 d](/filings/0001681622-25-000108.md) | [4.2](/filings/0001681622-25-000015.md) | [7.7](/filings/0001681622-25-000063.md) | [9.3](/filings/0001681622-25-000084.md) | [10.9 d](/filings/0001681622-25-000108.md) | [11.2](/filings/0001681622-26-000016.md) | [22.1](/filings/0001681622-26-000052.md) | [(80.7)](/filings/0001681622-26-000063.md) | [19.6 d](/filings/0001681622-25-000108.md) | [15.4](/filings/0001681622-26-000016.md) | [14.4](/filings/0001681622-26-000052.md) | [22.8](/filings/0001681622-26-000063.md) | | Interest expense | $m | [7.2 d](/filings/0001681622-23-000074.md) | [7.3](/filings/0001681622-24-000009.md) | [7.9](/filings/0001681622-24-000059.md) | [7.4](/filings/0001681622-25-000084.md) | [7.6 d](/filings/0001681622-25-000108.md) | [8.0](/filings/0001681622-26-000016.md) | [10.2](/filings/0001681622-26-000052.md) | [9.4](/filings/0001681622-26-000063.md) | [7.9 d](/filings/0001681622-25-000108.md) | [7.9](/filings/0001681622-26-000016.md) | [17.2](/filings/0001681622-26-000052.md) | [5.8](/filings/0001681622-26-000063.md) | | Income tax | $m | [(30.2) d](/filings/0001681622-25-000108.md) | [(0.2)](/filings/0001681622-25-000015.md) | [0.7](/filings/0001681622-25-000063.md) | [(0.7)](/filings/0001681622-25-000084.md) | [53.5 d](/filings/0001681622-25-000108.md) | [2.6](/filings/0001681622-26-000016.md) | [3.7](/filings/0001681622-26-000052.md) | [2.5](/filings/0001681622-26-000063.md) | [1.9 d](/filings/0001681622-25-000108.md) | [1.4](/filings/0001681622-26-000016.md) | [1.6](/filings/0001681622-26-000052.md) | [0.3](/filings/0001681622-26-000063.md) | | Net income | $m | [31.1 d](/filings/0001681622-25-000108.md) | [(0.5)](/filings/0001681622-25-000015.md) | [1.4](/filings/0001681622-25-000063.md) | [1.4](/filings/0001681622-25-000084.md) | [(51.1) d](/filings/0001681622-25-000108.md) | [(0.3)](/filings/0001681622-26-000016.md) | [6.9](/filings/0001681622-26-000052.md) | [(89.1)](/filings/0001681622-26-000063.md) | [12.2 d](/filings/0001681622-25-000108.md) | [2.3](/filings/0001681622-26-000016.md) | [(8.1)](/filings/0001681622-26-000052.md) | [15.7](/filings/0001681622-26-000063.md) | | Diluted EPS | $ per share | not reported | [(0.01)](/filings/0001681622-25-000015.md) | [0.03](/filings/0001681622-25-000063.md) | [0.03](/filings/0001681622-25-000084.md) | not reported | [(0.01)](/filings/0001681622-26-000016.md) | [0.17](/filings/0001681622-26-000052.md) | [(2.15)](/filings/0001681622-26-000063.md) | not reported | [0.05](/filings/0001681622-26-000016.md) | [(0.19)](/filings/0001681622-26-000052.md) | [0.37](/filings/0001681622-26-000063.md) | | Basic EPS | $ per share | not reported | [(0.01)](/filings/0001681622-25-000015.md) | [0.03](/filings/0001681622-25-000063.md) | [0.03](/filings/0001681622-25-000084.md) | not reported | [(0.01)](/filings/0001681622-26-000016.md) | [0.17](/filings/0001681622-26-000052.md) | [(2.15)](/filings/0001681622-26-000063.md) | not reported | [0.06](/filings/0001681622-26-000016.md) | [(0.19)](/filings/0001681622-26-000052.md) | [0.37](/filings/0001681622-26-000063.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-09-29) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | FY2024 (2024-09-27) | Q1 FY2025 (2025-01-03) | Q2 FY2025 (2025-04-04) | Q3 FY2025 (2025-07-04) | FY2025 (2025-10-03) | Q1 FY2026 (2026-01-02) | Q2 FY2026 (2026-04-03) | Q3 FY2026 (2026-07-03) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [153](/filings/0001681622-25-000108.md) | [141](/filings/0001681622-25-000015.md) | [142](/filings/0001681622-25-000063.md) | [156](/filings/0001681622-25-000084.md) | [169](/filings/0001681622-26-000063.md) | [176](/filings/0001681622-26-000016.md) | [205](/filings/0001681622-26-000052.md) | [136](/filings/0001681622-26-000063.md) | [145](/filings/0001681622-26-000063.md) | [120](/filings/0001681622-26-000016.md) | [85.3](/filings/0001681622-26-000052.md) | [99.2](/filings/0001681622-26-000063.md) | | Current assets | $m | [658](/filings/0001681622-24-000089.md) | [646](/filings/0001681622-24-000009.md) | [652](/filings/0001681622-24-000059.md) | [649](/filings/0001681622-24-000070.md) | [650](/filings/0001681622-25-000108.md) | [657](/filings/0001681622-25-000015.md) | [684](/filings/0001681622-25-000063.md) | [620](/filings/0001681622-25-000084.md) | [642](/filings/0001681622-26-000063.md) | [634](/filings/0001681622-26-000016.md) | [626](/filings/0001681622-26-000052.md) | [633](/filings/0001681622-26-000063.md) | | Total assets | $m | [1,250](/filings/0001681622-24-000089.md) | [1,242](/filings/0001681622-24-000009.md) | [1,252](/filings/0001681622-24-000059.md) | [1,253](/filings/0001681622-24-000070.md) | [1,214](/filings/0001681622-25-000108.md) | [1,332](/filings/0001681622-25-000015.md) | [1,358](/filings/0001681622-25-000063.md) | [1,073](/filings/0001681622-25-000084.md) | [1,107](/filings/0001681622-26-000063.md) | [1,098](/filings/0001681622-26-000016.md) | [1,089](/filings/0001681622-26-000052.md) | [1,100](/filings/0001681622-26-000063.md) | | Current liabilities | $m | [163](/filings/0001681622-24-000089.md) | [150](/filings/0001681622-24-000009.md) | [154](/filings/0001681622-24-000059.md) | [195](/filings/0001681622-24-000070.md) | [196](/filings/0001681622-25-000108.md) | [151](/filings/0001681622-25-000015.md) | [169](/filings/0001681622-25-000063.md) | [177](/filings/0001681622-25-000084.md) | [187](/filings/0001681622-26-000063.md) | [163](/filings/0001681622-26-000016.md) | [195](/filings/0001681622-26-000052.md) | [187](/filings/0001681622-26-000063.md) | | Total liabilities | $m | [669](/filings/0001681622-24-000089.md) | [659](/filings/0001681622-24-000009.md) | [662](/filings/0001681622-24-000059.md) | [657](/filings/0001681622-24-000070.md) | [670](/filings/0001681622-25-000108.md) | [778](/filings/0001681622-25-000015.md) | [794](/filings/0001681622-25-000063.md) | [604](/filings/0001681622-25-000084.md) | [621](/filings/0001681622-26-000063.md) | [607](/filings/0001681622-26-000016.md) | [601](/filings/0001681622-26-000052.md) | [590](/filings/0001681622-26-000063.md) | | Long-term debt | $m | [441](/filings/0001681622-24-000089.md) | [441](/filings/0001681622-24-000009.md) | [441](/filings/0001681622-24-000059.md) | [397](/filings/0001681622-24-000070.md) | [397](/filings/0001681622-25-000108.md) | [566](/filings/0001681622-25-000015.md) | [566](/filings/0001681622-25-000063.md) | [366](/filings/0001681622-25-000084.md) | [366](/filings/0001681622-26-000063.md) | [366](/filings/0001681622-26-000016.md) | [329](/filings/0001681622-26-000052.md) | [329](/filings/0001681622-26-000063.md) | | Current portion of debt | $m | [1.5](/filings/0001681622-24-000089.md) | [1.6](/filings/0001681622-24-000009.md) | [1.5](/filings/0001681622-24-000059.md) | [46.2](/filings/0001681622-24-000070.md) | [46.3](/filings/0001681622-25-000108.md) | [1.4](/filings/0001681622-25-000015.md) | [1.4](/filings/0001681622-25-000063.md) | [1.5](/filings/0001681622-25-000084.md) | [1.5](/filings/0001681622-26-000063.md) | [1.4](/filings/0001681622-26-000016.md) | [18.6](/filings/0001681622-26-000052.md) | [18.2](/filings/0001681622-26-000063.md) | | Shareholders' equity | $m | [568](/filings/0001681622-24-000089.md) | [569](/filings/0001681622-24-000009.md) | [576](/filings/0001681622-24-000059.md) | [581](/filings/0001681622-24-000070.md) | [529](/filings/0001681622-25-000108.md) | [540](/filings/0001681622-25-000015.md) | [550](/filings/0001681622-25-000063.md) | [455](/filings/0001681622-25-000084.md) | [473](/filings/0001681622-26-000063.md) | [477](/filings/0001681622-26-000016.md) | [474](/filings/0001681622-26-000052.md) | [497](/filings/0001681622-26-000063.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-09-29) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | Q4 FY2024 (2024-09-27) | Q1 FY2025 (2025-01-03) | Q2 FY2025 (2025-04-04) | Q3 FY2025 (2025-07-04) | Q4 FY2025 (2025-10-03) | Q1 FY2026 (2026-01-02) | Q2 FY2026 (2026-04-03) | Q3 FY2026 (2026-07-03) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [47.1 d](/filings/0001681622-25-000108.md) | [10.3](/filings/0001681622-25-000015.md) | [3.1 d](/filings/0001681622-25-000063.md) | [8.0 d](/filings/0001681622-25-000084.md) | [25.9 d](/filings/0001681622-25-000108.md) | [9.5](/filings/0001681622-26-000016.md) | [16.6 d](/filings/0001681622-26-000052.md) | [7.7 d](/filings/0001681622-26-000063.md) | [7.9 d](/filings/0001681622-25-000108.md) | [(16.1)](/filings/0001681622-26-000016.md) | [(1.5) d](/filings/0001681622-26-000052.md) | [21.0 d](/filings/0001681622-26-000063.md) | | Capital expenditure | $m | [5.4 d](/filings/0001681622-25-000108.md) | [10.4](/filings/0001681622-25-000015.md) | [5.8 d](/filings/0001681622-25-000063.md) | [4.7 d](/filings/0001681622-25-000084.md) | [6.0 d](/filings/0001681622-25-000108.md) | [4.2](/filings/0001681622-26-000016.md) | [6.8 d](/filings/0001681622-26-000052.md) | [6.3 d](/filings/0001681622-26-000063.md) | [5.6 d](/filings/0001681622-25-000108.md) | [10.7](/filings/0001681622-26-000016.md) | [6.2 d](/filings/0001681622-26-000052.md) | [9.0 d](/filings/0001681622-26-000063.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q1 FY2023 (2022-12-30) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-29) | Q2 FY2024 (2024-03-29) | Q3 FY2024 (2024-06-28) | Q1 FY2025 (2025-01-03) | Q2 FY2025 (2025-04-04) | Q3 FY2025 (2025-07-04) | Q1 FY2026 (2026-01-02) | Q2 FY2026 (2026-04-03) | Q3 FY2026 (2026-07-03) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [40.6](/filings/0001681622-24-000009.md) | [40.5](/filings/0001681622-24-000059.md) | [50.4](/filings/0001681622-24-000070.md) | [40.6](/filings/0001681622-25-000015.md) | [41.2](/filings/0001681622-25-000063.md) | [41.2](/filings/0001681622-25-000084.md) | [41.1](/filings/0001681622-26-000016.md) | [51.2](/filings/0001681622-26-000052.md) | [41.5](/filings/0001681622-26-000063.md) | [42.3](/filings/0001681622-26-000016.md) | [42.0](/filings/0001681622-26-000052.md) | [42.6](/filings/0001681622-26-000063.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 42,100,000 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001681622-26-000063.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.